In recognition of Lung Cancer Awareness Month, Massachusetts General Hospital physicians answer common questions related to lung cancer.
Henning Willers, MD
Henning Willers, MD
Director, Thoracic Radiation Oncology Program
Director, Radiation Biology & Research Program
Associate Professor, Harvard Medical School
Departments, Centers, & Programs:
Mass General Cancer Center: Radiation Oncology
55 Fruit St.
Lunder Building, LL3
Boston, MA 02114
- MD, University of Hamburg School of Medicine
- Residency, Massachusetts General Hospital*****
- Fellowship, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital*****
American Board Certifications
- Radiation Oncology, American Board of Radiology
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Willers' clinical research activities focus on: Developing personalized, high-precision radiation treatment approaches for tumors in the chest (https://www.massgeneral.org/cancer-center/radiation-oncology/treatments-and-services/imart-plus). Using proton beam radiation therapy in lung cancer to improve therapeutic efficacy and sparing of normal organs. The application of stereotactic body radiation therapy (SBRT) in patients with early-stage and metastatic NSCLC as well as lung metastases. Dr. Willers? clinical trials at https://clinicaltrials.gov NCT02314364, NCT02394548, NCT01993810, NCT01553942 Dr. Willers' lab research program aims at improving the outcomes of radiation therapy and identifying markers of resistance or sensitivity to radiation. There are three major focus areas: To understand and overcome genomically defined radiation resistance in lung cancer. To develop novel, biomarker-driven combinations of radiation with molecular targeted drugs in lung and other difficult-to-treat cancers. To target DNA repair pathways in lung and other cancers with proton radiation and PARP inhibitor treatments. Dr. Willers' long-term goal is to advance precision or "personalized" cancer therapy for patients with curable cancers.
Out of 94 peer-reviewed publications:
Li Y, Dykstra M, Best TD, Pursley J, Chopra N, Keane FK, Khandekar MJ, Sharp GC, Paganetti H, Willers H*, Fintelmann FJ*, Grassberger C*. Differential inflammatory response dynamics in normal lung following stereotactic body radiation therapy with protons versus photons. Radiother Oncol. 2019 May;134:151-157
Lebow ES, Hwang WL, Zieminski S, Wang Y, Niemierko A, Mehan WA Jr, Oh KS, Khandekar M, Willers H, Shih HA. Early experience with hippocampal avoidance whole brain radiation therapy and simultaneous integrated boost for brain metastases. J Neurooncol. 2020 May;148(1):81-88.
Roberts TJ, Lennes IT, Hawari S, Sequist LV, Park ER, Willers H, Frank A, Gaissert H, Shepard JA, Ryan D. Integrated, Multidisciplinary Management of Pulmonary Nodules Can Streamline Care and Improve Adherence to Recommendations. Oncologist. 2020 May;25(5):431-437.
Keane FK, Driscoll E, Bowes B, Durgin B, Khandekar MJ, Willers H. Low rates of chest wall toxicity when individualizing the planning target volume margin in early-stage lung cancer patients treated with stereotactic body radiation therapy. Pract Radiat Oncol. 2020 Oct 24;S1879-8500(20)30252-6
Kamran SC, Yeap BY, Ulysse CA, Cronin C, Bowes CL, Durgin B, Gainor JF, Khandekar MJ, Tansky JY, Keane FK, Olsen CC, Willers H. Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol. 2021 Apr 8:e210281.
Related News and Articles
- Press Release
- Apr | 22 | 2021
Radiation oncologists demonstrate in an early clinical trial that the radiation beam can be carefully “sculpted” to deliver the majority of a dose directly to the tumor while effectively sparing tissues in the side of the esophagus away from the affected lung.
- May | 21 | 2018
Drs. Henning Willers and David Miyamoto were recognized with a $150,000 grant to support their research proposal on investigating mechanisms of DNA repair after proton radiation.
- May | 15 | 2018
A task force commissioned by ASTRO reported the findings of its review on opportunities to expand the number of clinical trials that include radiation therapy in combination with new cancer drugs.